A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Treatment-Resistant Depression Registry investigated whether adjunctive vagus nerve stimulation (VNS) with treatment as usual in depression has superior long-term outcomes compared with treatment as usual only. METHOD: This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients who were experiencing a major depressive episode (unipolar or bipolar depression) of at least 2 years' duration or had three or more depressive episodes (including the current episode), and who had failed four or more depression treatments (including ECT). Patients with a history of psychosis or rapid-cycling bipolar disorder were excluded. The primary efficacy measure was response rate, defined as a decrease of ≥50% in baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score at any postbaseline visit during the 5-year study. Secondary efficacy measures included remission. RESULTS: Patients had chronic moderate to severe depression at baseline (the mean MADRS score was 29.3 [SD=6.9] for the treatment-as-usual group and 33.1 [SD=7.0] for the adjunctive VNS group). The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%). A subanalysis demonstrated that among patients with a history of response to ECT, those in the adjunctive VNS group had a significantly higher 5-year cumulative response rate than those in the treatment-as-usual group (71.3% compared with 56.9%). A similar significant response differential was observed among ECT nonresponders (59.6% compared with 34.1%). CONCLUSIONS: This registry represents the longest and largest naturalistic study of efficacy outcomes in treatment-resistant depression, and it provides additional evidence that adjunctive VNS has enhanced antidepressant effects compared with treatment as usual in this severely ill patient population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, stimulation of the vagus nerve (one of the core interoceptive neural pathways) has been successfully used as a means of treating depression (Aaronson et al., 2017).”
From Atypical interoception as a common risk factor for psychopathology: A review (2021) · cites this paper as Aaronson et al., 2017
In the citing paper
“This was even the case in patients with comorbid depression and anxiety who are frequent non-responders in trials on antidepressant drugs.”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [116]
In the citing paper
“Further, a 5-year prospective observational study which compared the effects of treatment as usual and VNS as adjunctive treatment with treatment as usual only in treatment-resistant depression, showed a better clinical outcome and a higher remission rate in the VNS group (116).”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [116]
Citations
Cites
1 retracted
Hollon, S. D., DeRubeis, R. J., Fawcett, J., Amsterdam, J. D., Shelton, R. C., Zajecka, J., Young, P. R., & Gallop, R. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1054 · Cited by 179 · cited 1×
“Given ethical concerns about following such a severely ill patient population over a 5-year period, the registry had a naturalistic, observational design and did not randomly assign patients to the treatment groups (22, 23).”
Self-citationRetractedThe central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1976) · Medical Entomology and Zoology · Cited by 8,899
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 1×
“TheMontgomeryÅsberg Depression Rating Scale (MADRS) (12) (administered by central raters), the Quick Inventory of Depressive Symptomatology–Self Report (QIDS-SR) (13, 14), the CGI improvement (CGI-I) score, and the patient-rated Frequency, Intensity, andBurdenofSideEffectsRating scale (15) were administered, and data…”
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 10×
“Secondary efficacy endpoints included response based on a CGI-I score of 1 or 2 at a postbaseline visit and an improvement of$50% frombaseline on theQIDS-SR; remission, based on aMADRS score #9 at a postbaseline visit, a QIDS-SR score #5 at a postbaselinevisit, andaCGI-I scoreof 1 at apostbaselinevisit; and duration o…”
MethodInfluentialThe Central Role of the Propensity Score in Observational Studies for Causal Effects
Rosenbaum, P. R., & Rubin, D. B. (1983) · Biometrika · doi:10.2307/2335942 · Cited by 3,261
Research works printed but not linked: 2
- Rush AJ, 2009, CNS Drugs, 23, 627
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
Cited by
Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders
Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00044 · Cited by 1,189
“Further, a 5-year prospective observational study which compared the effects of treatment as usual and VNS as adjunctive treatment with treatment as usual only in treatment-resistant depression, showed a better clinical outcome and a higher remission rate in the VNS group (116).”
BackgroundGut microbiota and its metabolites in depression: from pathogenesis to treatment
Liu, L., Wang, H., Chen, X., Zhang, Y., Zhang, H., & Xie, P. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104527 · Cited by 655
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
The role of inflammation and the gut microbiome in depression and anxiety
Peirce, J. M., & Alviña, K. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24476 · Cited by 466
“On a related note, electric vagus nerve stimulation has been shown to signifi‐ cantly improve mental health outcomes in patients with treatment‐ resistant depression compared to a control group (Aaronson et al., 2017).”
BackgroundDefining treatment‐resistant depression
Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman‐Hoffman, V., Green, J., Boland, E., Weber, R. P., Randolph, C., Bann, C., et al. (2020) · Depression and Anxiety · doi:10.1002/da.22968 · Cited by 447
“, the vagal nerve stimulation registry that the FDA requires (Aaronson et al., 2017; Naumann et al., 2017) and the transcranial magnetic stimulation registry recently launched by Neurostar (NeuroStar Advanced Therapy, 2017) and that have been suggested (e.”
BackgroundMethodMcAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
“, 2017], VNS [Aaronson et al., 2017] and deep brain stimulation [Kisely et al.”
BackgroundInfluentialHeart Rate Variability as Indicator of Clinical State in Depression
Hartmann, R., Schmidt, F. M., Sander, C., & Hegerl, U. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00735 · Cited by 236
Treatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256
International randomized-controlled trial of transcranial Direct Current Stimulation in depression
Loo, C. K., Husain, M. M., McDonald, W. M., Aaronson, S., O'Reardon, J. P., Alonzo, A., Weickert, C. S., Martin, D. M., McClintock, S. M., Mohan, A., et al. (2018) · Brain Stimulation · doi:10.1016/j.brs.2017.10.011 · Cited by 222
Self-citationA Comprehensive Review of Vagus Nerve Stimulation for Depression
Austelle, C. W., O'Leary, G. H., Thompson, S., Gruber, E., Kahn, A., Manett, A. J., Short, B., & Badran, B. W. (2022) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.13528 · Cited by 201
Sackeim, H. A., Aaronson, S. T., Carpenter, L. L., Hutton, T. M., Mina, M., Pages, K., Verdoliva, S., & West, W. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.08.005 · Cited by 201
Self-citationVagus nerve stimulation in brain diseases: Therapeutic applications and biological mechanisms
Wang, Y., Zhan, G., Cai, Z., Jiao, B., Zhao, Y., Li, S., & Luo, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.04.018 · Cited by 206
Vagal nerve stimulation for treatment-resistant depression
Carreno, F. R., & Frazer, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0537-8 · Cited by 208
“[51] published a 5-year follow-up to their previous study comparing the effects of VNS or TAU in patients with TRD carried out for 50 weeks.”
BackgroundCrowell, A. L., Riva-Posse, P., Holtzheimer, P. E., Garlow, S. J., Kelley, M. E., Gross, R. E., Denison, L., Quinn, S., & Mayberg, H. S. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18121427 · Cited by 182
Atypical interoception as a common risk factor for psychopathology: A review
Brewer, R., Murphy, J., & Bird, G. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.036 · Cited by 180
Superolateral medial forebrain bundle deep brain stimulation in major depression: a gateway trial
Coenen, V. A., Bewernick, B. H., Kayser, S., Kilian, H., Boström, J., Greschus, S., Hurlemann, R., Klein, M. E., Spanier, S., Sajonz, B., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0369-9 · Cited by 176
“As we have learned from studies on the antidepressant effects of vagus nerve stimulation, the peak effect of a treatment might be observable at a later time point than previously expected [38].”
BackgroundNeuromodulation techniques – From non-invasive brain stimulation to deep brain stimulation
Davidson, B., Bhattacharya, A., Sarica, C., Darmani, G., Raies, N., Chen, R. E., & Lozano, A. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00330 · Cited by 189
“Given its positive mood effects during epilepsy treatment, similar stimulation frequency and duty-cycle parameters have been used, with a dose-fi nding study suggesting higher pulse width and amplitudes (within a tolerable range) are optimal [195].”
BackgroundMethodBottomley, J. M., LeReun, C., Diamantopoulos, A., Mitchell, S., & Gaynes, B. N. (2020) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.152156 · Cited by 138
The vagus afferent network: emerging role in translational connectomics
Hachem, L. D., Wong, S. M., & Ibrahim, G. M. (2018) · Neurosurgical FOCUS · doi:10.3171/2018.6.focus18216 · Cited by 151
Oral selective serotonin reuptake inhibitors activate vagus nerve dependent gut-brain signalling
McVey Neufeld, K.-A., Bienenstock, J., Bharwani, A., Champagne-Jorgensen, K., Mao, Y., West, C., Liu, Y., Surette, M. G., Kunze, W., & Forsythe, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-50807-8 · Cited by 132
Closing the Loop on Deep Brain Stimulation for Treatment-Resistant Depression
Widge, A. S., Malone, D. A., & Dougherty, D. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00175 · Cited by 143
Self-citationThe immune system and psychiatric disease: a basic science perspective
Bennett, F. C., & Molofsky, A. V. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13334 · Cited by 137
Interoception and Inflammation in Psychiatric Disorders
Savitz, J., & Harrison, N. A. (2018) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.12.011 · Cited by 126
“Perhaps the clearest example of a therapy directly targeting interoceptive mechanisms is vagus nerve stimulation, which exhibits potent predepressant properties (132).”
BackgroundDifficult-to-treat depression: A clinical and research roadmap for when remission is elusive
Rush, A. J., Aaronson, S. T., & Demyttenaere, K. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418808585 · Cited by 120
“For example, a sub-analysis of patients receiving vagus nerve stimulation (VNS) showed a significantly higher likelihood of response to VNS if the patient had historically responded to ECT (71.5% vs 59.7%; Aaronson et al., 2017).”
ResultInfluentialSelf-citationRecognizing the role of the vagus nerve in depression from microbiota-gut brain axis
Tan, C., Yan, Q., Ma, Y., Fang, J., & Yang, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1015175 · Cited by 130
The Microbiota-Gut-Immune-Glia (MGIG) Axis in Major Depression
Rudzki, L., & Maes, M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01961-y · Cited by 111
Vagal Mediation of Low-Frequency Heart Rate Variability During Slow Yogic Breathing
Kromenacker, B. W., Sanova, A. A., Marcus, F. I., Allen, J. J. B., & Lane, R. D. (2018) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000603 · Cited by 114
Prebiotic and Probiotic Modulation of the Microbiota–Gut–Brain Axis in Depression
Radford-Smith, D. E., & Anthony, D. C. (2023) · Nutrients · doi:10.3390/nu15081880 · Cited by 96
“Reciprocally, vagus nerve stimulation has been used as an adjunct treatment for severe depression [30].”
MethodSackeim, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., Demitrack, M. A., George, M. S., Prudic, J., Thase, M. E., & Rush, A. J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.021 · Cited by 109
“The ATHF was then applied in a variety of studies with other brain stimulation interventions, both to specify minimal and maximal levels of treatment resistance in samples and as a predictor of outcome (Aaronson et al., 2017; George et al., 2010; Lisanby et al., 2009; O'Reardon et al., 2007; Rush et al., 2005a; Sackei…”
MethodSelf-citationLasselin, J., Lekander, M., Axelsson, J., & Karshikoff, B. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.005 · Cited by 106
“A relatively new therapeutic intervention that has been tried for depression (Aaronson et al., 2017) and pain (Koopman et al.”
Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders
Bremner, J. D., Gurel, N. Z., Wittbrodt, M. T., Shandhi, M. M. H., Rapaport, M. H., Nye, J. A., Pearce, B. D., Vaccarino, V., Shah, A. J., Park, J., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030119 · Cited by 105
The gut-brain axis and cognitive control: A role for the vagus nerve
Décarie-Spain, L., Hayes, A., Lauer, L. T., & Kanoski, S. E. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.02.004 · Cited by 107
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 106
“Furthermore, a long naturalistic study of the efficacy of VNS as an adjunctive therapy for TRD revealed a 67.6% cumulative response rate over a 5-year period, which was significantly higher than the 40.9% response rate for the treatment-as-usual TRD patients [239].”
ResultInfluentialMelrose, J. (2023) · Antioxidants · doi:10.3390/antiox12030663 · Cited by 106
Dziedzic, A., Maciak, K., Bliźniewska-Kowalska, K. M., Gałecka, M., Kobierecka, W., & Saluk, J. (2024) · Nutrients · doi:10.3390/nu16071054 · Cited by 107
Clinical research challenges posed by difficult-to-treat depression.
Rush, A. J., Sackeim, H. A., Conway, C. R., Bunker, M. T., Hollon, S. D., Demyttenaere, K., Young, A. H., Aaronson, S. T., Dibué, M., Thase, M. E., et al. (2022) · Psychological Medicine · doi:10.1017/s0033291721004943 · Cited by 89
“One strategy to identify the target sample for new interventions in DTD is the use of patient registries, in which initial testing of an intervention in an open trial identifies the subgroups for which the intervention is more or less effective (Aaronson et al., 2017; Sackeim et al., 2020).”
Self-citationElectrical stimulation enhances neuronal cell activity mediated by Schwann cell derived exosomes
Hu, M., Li, H., Liu, C., Hong, S., He, S., Zhou, M., Huang, G., & Chen, Q. (2019) · Scientific Reports · doi:10.1038/s41598-019-41007-5 · Cited by 88
Gurel, N. Z., Huang, M., Wittbrodt, M. T., Jung, H., Ladd, S. L., Shandhi, M. M. H., Ko, Y., Shallenberger, L. H., Nye, J. A., Pearce, B. D., et al. (2019) · Brain stimulation · doi:10.1016/j.brs.2019.08.002 · Cited by 91
Chen, P., Wang, Q., Wan, X., Yang, M., Liu, C., Xu, C., Hu, B., Feng, J., & Luo, Z. (2021) · Nano Energy · doi:10.1016/j.nanoen.2021.106327 · Cited by 91
Gurel, N. Z., Wittbrodt, M. T., Jung, H., Shandhi, M. M. H., Driggers, E. G., Ladd, S. L., Huang, M., Ko, Y., Shallenberger, L. H., Beckwith, J., et al. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100264 · Cited by 86
“6 procedures as revealed by the high rates of non-com pliance in multi-year VNS studies due to the 1 biological and psychological effects of the surgica l mplantation (26, 27).”
BackgroundHeerlein, K., Perugi, G., Otte, C., Frodl, T., Degraeve, G., Hagedoorn, W., Oliveira-Maia, A. J., Pérez, V., Rathod, S., Rosso, G., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.073 · Cited by 89
“As in this study, the US Treatment-Resistant Depression Registry study (Aaronson et al., 2017) used clinician rated assessments (MADRS), and the baseline depression severity was comparable.”
Huang, J., Huang, W., Yi, J., Deng, Y., Li, R., Chen, J., Shi, J., Qiu, Y., Wang, T., Chen, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43150-0 · Cited by 81
“Vagus nerve stimulation (VNS) is an FDA-approved therapy for the treatment of depression, but it is limited in clinical application due to perioperative risks involved with device implantation 48 .”
BackgroundResearch progress of vagus nerve stimulation in the treatment of epilepsy
Fan, J., Shan, W., Wu, J., & Wang, Q. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13209 · Cited by 81
Electroconvulsive therapy in treatment resistant depression
Subramanian, S., Lopez, R., Zorumski, C. F., & Cristancho, P. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120095 · Cited by 85
Cognition-Enhancing Vagus Nerve Stimulation Alters the Epigenetic Landscape
Sanders, T. H., Weiss, J. B., Hogewood, L., Chen, L., Paton, C., McMahan, R. L., & Sweatt, J. D. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2407-18.2019 · Cited by 79
“, 2008) and positive effects on treatment-resistant depression (Nemeroff et al., 2006; Aaronson et al., 2017).”
BackgroundResultInfluentialMüller, H., Moeller, S., Lücke, C., Lam, A. P., Braun, N., & Philipsen, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00239 · Cited by 82
“Nonetheless, due to the solid magnitude of effects and the addition of a control group receiving other antidepressive treatment to the large D-23 registry trial (Aaronson et al., 2017), it seems unlikely that the observed effects were due to the placebo effect alone.”
BackgroundAljeradat, B., Kumar, D., Abdulmuizz, S., Kundu, M., Almealawy, Y. F., Batarseh, D. R., Atallah, O., Ennabe, M., Alsarafandi, M., Alan, A., et al. (2024) · Pathophysiology · doi:10.3390/pathophysiology31020019 · Cited by 78
“It functions by delivering periodic and gentle electrical energy pulses to the brain through the vagus nerve [7].”
BackgroundReutfors, J., Andersson, T., Tanskanen, A. J., DiBernardo, A., Li, G., Brandt, L., & Brenner, P. (2019) · Archives of Suicide Research · doi:10.1080/13811118.2019.1691692 · Cited by 77
“From a research methodology perspective, suicide is a rare outcome, and its risk factors in different populations may be difficult to study in a clinical setting (Aaronson et al., 2017).”
BackgroundKoenig, J., Parzer, P., Haigis, N., Liebemann, J., Jung, T., Resch, F., & Kaess, M. (2019) · Psychological Medicine · doi:10.1017/s0033291719003490 · Cited by 69
Prognosis and Improved Outcomes in Major Depression: A Review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2020) · Focus · doi:10.1176/appi.focus.18205 · Cited by 62
Effect of neurostimulation on cognition and mood in refractory epilepsy
Chan, A. Y., Rolston, J. D., Rao, V. R., & Chang, E. F. (2018) · Epilepsia Open · doi:10.1002/epi4.12100 · Cited by 69
Dalton, B., Bartholdy, S., Campbell, I. C., & Schmidt, U. H. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180108111532 · Cited by 69
“Although VNS is receiving a resurgence of interest in other disorders, such as depression [37, 38], we decided not to include this in the present review, as to the best of our knowledge, no studies have focused on using VNS in EDs.”
Ohemeng, K. K., & Parham, K. (2019) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2019.09.008 · Cited by 71
Wilkinson, S. T., Diaz, D. T., Rupp, Z. W., Kidambi, A., Ramírez, K. L., Flores, J. M., Avila-Quintero, V. J., Rhee, T. G., Olfson, M., & Bloch, M. H. (2021) · Depression and Anxiety · doi:10.1002/da.23222 · Cited by 68
“There was an insufficient number of studies (k = 2) to meta‐analyze the effects of VNS on suicide‐related outcomes (Aaronson et al., 2017; Olin et al., 2012).”
BackgroundVagus nerve stimulation: An update on a novel treatment for treatment-resistant depression
Kamel, L. Y., Xiong, W., Gott, B. M., Kumar, A., & Conway, C. R. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120171 · Cited by 67
Self-citationThe microbiota–gut–brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets
Ekwudo, M. N., Gubert, C., & Hannan, A. J. (2024) · FEBS Journal · doi:10.1111/febs.17102 · Cited by 65
“Consistent evidence suggests that VNS has promising potential as an add-on treatment for IBD [108], PD [109], treatment-resistant depression [110] and AD [111] but has not been investigated in HD yet.”
Petracco, G., Faimann, I., & Reichmann, F. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108831 · Cited by 64
Comparison and Selection of Current Implantable Anti-Epileptic Devices
Wong, S., Mani, R., & Danish, S. F. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00727-2 · Cited by 66
Zhou, J., Li, M., Wang, X., He, Y., Xia, Y., Sweeney, J. A., Kopp, R. F., Liu, C., & Chen, C. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.674273 · Cited by 56
Bremner, J. D., Wittbrodt, M. T., Gurel, N. Z., Shandhi, M. H., Gazi, A. H., Jiao, Y., Levantsevych, O. M., Huang, M., Beckwith, J., Herring, I., et al. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100190 · Cited by 55
“Implantable VNS devices are currently approved by the Food and Drug Administration (FDA) for treatment resistant major depression (Aaronson et al., 2017; George et al., 2003; Terry, 2014).”
BackgroundConway, C. R., Aaronson, S. T., Sackeïm, H. A., George, M. S., Zajecka, J., Bunker, M. T., Duffy, W. J., Stedman, M., Riva‐Posse, P., Allen, R. M., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.12.1191 · Cited by 57
“Response rates were lower than expected given prior open VNS trials [19,20,53], potentially due to participant characteristics, treatment history, and treatment delivery factors.”
InfluentialSelf-citationBrain stimulation treatment for bipolar disorder
Mutz, J. (2022) · Bipolar Disorders · doi:10.1111/bdi.13283 · Cited by 62
Long-term Sustained Cognitive Benefits of Vagus Nerve Stimulation in Refractory Depression
Jodoin, V. D., Richer, F., Miron, J., Fournier‐Gosselin, M., & Lespérance, P. (2018) · Journal of Ect · doi:10.1097/yct.0000000000000502 · Cited by 51
Neuro-immune interactions: Exploring the anti-inflammatory role of the vagus nerve
Liu, L., Lou, S., Fu, D., Ji, P., Xia, P., Shuang, S., Dong, W., Yuan, X., Wang, J., Xie, K., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114941 · Cited by 50
Eren, O. E., Filippopulos, F. M., Sönmez, K., Möhwald, K., Straube, A. M., & Schöberl, F. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8894-8 · Cited by 49
“Based on the reported therapeutic effects of vagus nerve stimulation in depression [9] on the one hand, and primary headache syndromes with significant activation of the ANS (i.”
BackgroundSakurai, H., Jain, F., Foster, S., Pedrelli, P., Mischoulon, D., Fava, M., & Cusin, C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.089 · Cited by 45
“In an observational study to examine the e ff ectiveness of adjunctive Vagal Nerve Stimulation (VNS), the cumulative response rate of treatment-as-usual at 3 months was less than 10% for those who had 7.3 failed treatments for depression (Aaronson et al., 2017).”
BackgroundInfluentialCan a Framework Be Established for the Safe Use of Ketamine?
Freedman, R., Brown, A. S., Cannon, T. D., Druss, B. G., Earls, F. J., Escobar, J. I., Hurd, Y. L., Lewis, D. A., López‐Jaramillo, C., Luby, J. L., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18030290 · Cited by 48
In vivo quantification of excitation and kilohertz frequency block of the rat vagus nerve
Pelot, N. A., & Grill, W. M. (2020) · Journal of Neural Engineering · doi:10.1088/1741-2552/ab6cb6 · Cited by 49
“Applications of vagus nerve stimulation (VNS) include treating epilepsy (Morris and Mueller 1999), depression (Aaronson et al 2017), obesity (Ikramuddin et al 2014), type 2 diabetes (Tweden et al 2016), heart failure (Gold et al 2016), rheumatoid arthritis (Koopman et al 2018), and Crohn’s disease…”
BackgroundTreatment-Resistant Late-Life Depression
Subramanian, S., Oughli, H. A., Gebara, M. A., Palanca, B. J. A., & Lenze, E. J. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.008 · Cited by 77
Bharwani, A., West, C. L., Champagne-Jorgensen, K., Neufeld, K. M., Ruberto, J., Kunze, W., Bienenstock, J., & Forsythe, P. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108067 · Cited by 47
Bremner, J. D., Gurel, N. Z., Jiao, Y., Wittbrodt, M. T., Levantsevych, O. M., Huang, M., Jung, H., Shandhi, M. H., Beckwith, J., Herring, I., et al. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100138 · Cited by 54
“FDA-approved VNS for these conditions involves surgical implantation in the brainstem with direct electrical stimulation of the vagus nerve (Aaronson et al., 2017; George et al., 2003; Terry, 2014).”
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
Aaronson, S. T., van der Vaart, A. D., Miller, T. L., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M. D., Suppes, T. M., & Sackeïm, H. A. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20231063 · Cited by 46
Self-citationKumar, A., Bunker, M. T., Aaronson, S. T., Conway, C. R., Rothschild, A. J., Mordenti, G., & Rush, A. J. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s196665 · Cited by 44
“statistical analysis Of the 494 participants in the VNS + TAU arm reported in Aaronson et al, 159 participants who had “crossed over” from VNS treatment in the previously reported flexible dose study were excluded, as most of these subjects had only 1 year of consistent follow-up data and our study aimed to understand…”
BackgroundMethodResultInfluentialSelf-citationPope, B. S., & Wood, S. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.031 · Cited by 48
Chen, Y., Meng, P., Cheng, S., Jia, Y., Wen, Y. F., Yang, X., Yao, Y., Pan, C., Li, C., Zhang, H., et al. (2021) · Molecular Brain · doi:10.1186/s13041-021-00843-1 · Cited by 47
Holland, M. T., Trapp, N. T., McCormick, L. M., Jareczek, F. J., Zanaty, M., Close, L. N., Beeghly, J., & Greenlee, J. D. W. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00055 · Cited by 39
Conway, C. R., Olin, B., Aaronson, S. T., Sackeïm, H. A., Bunker, M. T., Kriedt, C. L., Greco, T., Broglio, K., Vestrucci, M., & Rush, A. J. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106066 · Cited by 43
Self-citationThe Efficacy and Safety of Neuromodulation Treatments in Late-Life Depression
van Rooij, S. J. H., Riva-Posse, P., & McDonald, W. M. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00216-w · Cited by 38
Multiple-therapy-resistant major depressive disorder: a clinically important concept
McAllister-Williams, R. H., Christmas, D. M. B., Cleare, A. J., Currie, A., Gledhill, J., Insole, L., Malizia, A. L., McGeever, M., Morriss, R., Robinson, L. J., et al. (2018) · British Journal of Psychiatry · doi:10.1192/bjp.2017.33 · Cited by 40
ADHD-originating in the gut? The emergence of a new explanatory model
Sandgren, A. M., & Brummer, R. J. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.08.022 · Cited by 45
Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?
da Costa, L. H. A., Santos, B. M., & Branco, L. G. S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173629 · Cited by 42
Treatment-resistant bipolar depression: concepts and challenges for novel interventions
Díaz, A. P., Fernandes, B. S., Quevedo, J., Sanches, M., & Soares, J. C. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1627 · Cited by 42
Neurostimulation for depression in epilepsy
Conway, C. R., Anita, U., & Schachter, S. C. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.06.007 · Cited by 38
Self-citationSpindler, P., Bohlmann, K., Straub, H., Vajkoczy, P., & Schneider, U. C. (2019) · Seizure · doi:10.1016/j.seizure.2019.04.001 · Cited by 37
Havton, L. A., Biscola, N. P., Stern, E., Mihaylov, P. V., Kubal, C. A., Wo, J. M., Gupta, A., Baronowsky, E. A., Ward, M. P., Jaffey, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03248-1 · Cited by 35
McAllister-Williams, H., Sousa, S., Kumar, A., Greco, T., Bunker, M. T., Aaronson, S. T., Conway, C. R., & Rush, A. J. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-020-0178-4 · Cited by 34
Self-citationDibué, M., Kamp, M. A., & Vonck, K. E. J. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.02.004 · Cited by 31
Beyond evidence‐based treatment of bipolar disorder: Rational pragmatic approaches to management
Post, R. M., Yatham, L. N., Vieta, E., Berk, M., & Nierenberg, A. A. (2019) · Bipolar Disorders · doi:10.1111/bdi.12813 · Cited by 31
Grigoroglou, C., Feltz-Cornelis, C. M. V. D., Hodkinson, A., Coventry, P. A., Zghebi, S. S., Kontopantelis, E., Bower, P., Lovell, K., Gilbody, S. M., Waheed, W., et al. (2021) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2021.04.004 · Cited by 35
Young, A. H., Juruena, M. F., Zwaef, R. D., & Demyttenaere, K. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02869-6 · Cited by 31
Garcia, R. G., Cohen, J. E., Stanford, A. D., Gabriel, A. S., Stowell, J. A., Aizley, H. G., Barbieri, R., Gitlin, D., Napadow, V., & Goldstein, J. M. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.07.048 · Cited by 30
Bao, S., Lu, Y., Zhang, J., Xue, L., Zhang, Y., Wang, P., Zhang, F., Gu, N., & Sun, J. (2023) · Nanoscale · doi:10.1039/d2nr05073k · Cited by 32
Lespérance, P., Jodoin, V. D., Drouin, D., Racicot, F., Miron, J., Longpré-Poirier, C., Fournier‐Gosselin, M., Thébault, P., Lapointe, R., Arbour, N., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052679 · Cited by 33
“Yet, a recent 5-year longitudinal registry study of almost 500 patients did find strong evidence for long-term benefits of VNS therapy on over 300 patients in the treatment-as-usual (TAU) group, and a lower relapse rate, rekindling interest in this technology in TRD [13].”
BackgroundAnalysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies
Huang, B., Tian, L., McCaw, Z. R., Luo, X., Talukder, E., Rothenberg, M. L., Xie, W., Choueiri, T. K., Kim, D. H., & Wei, L. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0104 · Cited by 30
“For instance, in a recent study that compared adjunctive vagus nerve stimulation with standard care in treatmentresistant depression, the primary efficacy measure was cumulative response, defined as a 50% decrease from the baseline depression score at any follow-up visit across 5 years (3).”
ResultSarasso, P., Billeci, M., Ronga, I., Raffone, F., Martiadis, V., & Petta, G. D. (2024) · Psychopathology · doi:10.1159/000539714 · Cited by 32
“Experimental re-sults support this hypothesis by showing that interoceptive awareness [34, 105, 108, 109] and interoceptive cortex activation [110 – 112] are altered in depression and negatively correlate with symptoms severity [34, 105, 113].”
Reddy, S. D., Kabotyanski, K. E., Hirani, S., Liu, T. B.-L., Naqvi, Z. U., Giridharan, N., Hasen, M., Provenza, N. R., Banks, G. P., Mathew, S. J., et al. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.08.013 · Cited by 32
Wasilczuk, K. M., Bayer, K. C., Somann, J. P., Albors, G. O., Sturgis, J. E., Lyle, L. T., Robinson, J. P., & Irazoqui, P. P. (2018) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2018.09.005 · Cited by 33
Fetzer, S., Dibué, M., Nagel, A. M., & Trollmann, R. (2021) · Neuroradiology · doi:10.1007/s00234-021-02705-y · Cited by 29
“Among adults with depression, more than 25% experience treatment-resistant depression (TRD) that encompasses considerable morbidity and adverse effects on quality of life.”
BackgroundInfluentialA Causal Network Analysis of Neuromodulation in the Mood Processing Network
Qiao, S., Sedillo, J. I., Brown, K. A., Ferrentino, B., & Pesaran, B. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.012 · Cited by 29
Giakoumatos, C. I., & Osser, D. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000197 · Cited by 27
“These options range from minimally evidenced, often novel psychopharmacology strategies to invasive, device-based or surgical techniques such as vagus nerve stimulation.(189) Decisions to employ these options are highly influenced by local interest, availability, and cost considerations.”
Background
Metadata
- Authors
- Aaronson, S. T., Sears, P., Ruvuna, F., Bunker, M., Conway, C. R., Dougherty, D. D., Reimherr, F. W., Schwartz, T. L., & Zajecka, J. M.
- Affiliations
- Rush University Medical Center (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2017-07-01
- Volume
- 174
- Issue
- 7
- Pages
- 640-648
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2599051175
- Cited by
- 381
- References
- 26
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 54 · 2023: 34 · 2022: 40 · 2021: 39 · 2020: 43 · 2019: 47 · 2018: 37 · 2017: 8
- FWCI
- 18.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- treatment-resistant depression, vagus nerve stimulation, adjunctive therapy, response rate, remission, suicidality, bipolar depression, major depressive disorder, long-term outcomes
- MeSH terms
- Adult, Bipolar Disorder, Chronic Disease, Depressive Disorder, Major, Major Depressive Disorder, Electroconvulsive Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Registries, Treatment Outcome, Vagus Nerve Stimulation, Suicidal Ideation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.